Press Release
<p>WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD</p>
<p>Contact: Christine Stroup <strong>FOR IMMEDIATE RELEASE</strong><br/>
Kovak-Likly Communications<br/>
(203) 762-8833 or<br/>
CStroup@KLCpr.com </p>
<p><strong>Ferring Pharmaceuticals Announces</strong><br/>
<strong>2008 My Little Miracle Essay Contest</strong> </p>
<p>PARSIPPANY, NJ – April 9, 2008 - If you are a parent who has successfully given birth
using Ferring Pharmaceuticals’ fertility products, you can win a $10,000 education fund to
support your child’s future. Eleven other education fund prizes will also be awarded. To
be eligible, all you need to do is write a brief essay. The topic is: If I Knew Then What I
Know Now, explaining what advice you would give to other women who are just beginning
their journey to parenthood and how you would describe your success using BRAVELLE<sup>®</sup>
(urofollitropin for injection, purified) and/or MENOPUR <sup>®</sup> (menotropins for injection, USP)
as part of your treatment plan. </p>
<p>Ferring’s My Little Miracle Essay Contest is open to women who have been
successfully treated with BRAVELLE<sup>®</sup> and/or MENOPUR<sup>®</sup>. The contest celebrates the
miracle of birth for parents who have faced infertility, and carries on Ferring’s tradition of
supporting patients by offering education funds for the winners’ children. </p>
<p>Ferring is also awarding a $2,500 education fund to the runner up and $500 each to
10 honorable mention winners. Since announcing the first contest in 2004, Ferring has
awarded $85,000 in education funds. </p>
<p>Essays should not exceed 2,000 words. They must be written in English, include
the entrant’s name, address, phone number and age, as well as the child(ren)’s name(s)
and age(s), and be submitted with a contest application and labeled digital photo. Entries
must be postmarked by August 30, 2008. Winners will be announced at the 64th Annual
Meeting of the American Society for Reproductive Medicine (ASRM)/, November 8-12, 2008. </p>
<p>For more details and a contest application, visit www.ferringfertility.com or
www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay
Contest representative. </p>
<p>BRAVELLE<sup>®</sup> and MENOPUR <sup>®</sup>, like all gonadotropins, are potent substances
capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0%
and 3.8%, respectively), with or without pulmonary or vascular complications, in women
undergoing therapy for infertility. </p>
<p>The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in<br/>
naturally occurring protein hormones. Only physicians thoroughly familiar with infertility
treatment, including the risk of multiple births and adverse reactions, should prescribe
these medications. Like other products for ovarian stimulation, treatment with
BRAVELLE<sup>®</sup> and/or MENOPUR <sup>®</sup> may result in multiple gestations. </p>
<p><strong>About Ferring Pharmaceuticals</strong><br/>
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international
pharmaceutical company, manufactures and markets the largest family of
fertility treatments of any manufacturer in the U.S. The Company markets BRAVELLE<sup>®</sup>,
MENOPUR<sup>®</sup>, REPRONEX<sup>®</sup> (menotropins for injection, USP), NOVAREL<sup>®</sup> (chorionic
gonadotropin for injection, USP) and ENDOMETRIN<sup>®</sup> (progesterone) Vaginal Insert, 100
mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q·CAP™,
the first and only needle-free reconstitution device, for use with its fertility treatments.</p>
<p>Ferring’s line of orthopaedic and urology products includes EUFLEXXA™,
hyaluronic acid for pain from osteoarthritis in the knee. Other products include:
ACTHREL<sup>®</sup> (corticorelin ovine triflutate for injection) for the differential diagnosis of
Cushing’s syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for
the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED<sup>®</sup>/DS for
the relief of discomfort of the lower urinary tract. </p>
<p>The Ferring Group specializes in the research, development and commercialization
of compounds in general and pediatric endocrinology, urology, gastroenterology,
obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit
www.ferringusa.com or www.ferringfertility.com.<br/>
# # #<br/>
Please contact Christine Stroup for full prescribing information. </p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
